Common Cold-An Update.

Abstract

Abstract: The common cold, a mild yet highly prevalent upper respiratory tract infection (URTI), imposes a substantial societal and economic burden through healthcare costs, lost productivity, and widespread morbidity. Primarily caused by diverse respiratory viruses (e.g., rhinoviruses, coronaviruses), it encompasses a spectrum of acute infections affecting the nasal passages, throat, larynx, and bronchi, manifesting as rhinitis, pharyngitis, or bronchitis. Framed by the "iceberg concept" of disease, most cases are mild or asymptomatic, yet severe outcomes (e.g., exacerbations of chronic conditions) contribute to rare mortality. Management focuses on symptom relief: decongestants and antihistamines alleviate nasal congestion and cough in adults, though cough suppressants are discouraged in children. Despite its self-limiting nature, the common cold underscores challenges in primary care due to viral diversity and a lack of targeted therapies. Annual influenza vaccination, while not preventing colds, mitigates flu-related complications, indirectly reducing overlapping URTI burdens. Public health strategies emphasizing prevention, symptom management, and judicious antibiotic use remain critical to curbing its widespread impact.